Related Experiment Video
Updated: Oct 30, 2025
Immunolabelling Myofiber Degeneration in Muscle Biopsies
Published on: December 5, 2019
Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy
Sharon Mordechay1, Shaun Smullen2, Paul Evans2
1Department of Animal Sciences, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel.
Abstract:
Progressive loss of muscle and muscle function is associated with significant fibrosis in Duchenne muscular dystrophy (DMD) patients. Halofuginone, an analog of febrifugine, prevents fibrosis in various animal models, including those of muscular dystrophies. Effects of (+)/(-)-halofuginone enantiomers on motor coordination and diaphragm histopathology in mdx mice, the mouse model for DMD, were examined. Four-week-old male mice were treated with racemic halofuginone, or its separate enantiomers, for 10 weeks. Controls were treated with saline. Racemic halofuginone-treated mice demonstrated better motor coordination and balance than controls. However, (+)-halofuginone surpassed the racemic form's effect. No effect was observed for (-)-halofuginone, which behaved like the control. A significant reduction in collagen content and degenerative areas, and an increase in utrophin levels were observed in diaphragms of mice treated with racemic halofuginone. Again, (+)-halofuginone was more effective than the racemic form, whereas (-)-halofuginone had no effect. Both racemic and (+)-halofuginone increased diaphragm myofiber diameters, with no effect for (-)-halofuginone. No effects were observed for any of the compounds tested in an in-vitro cell viability assay. These results, demonstrating a differential effect of the halofuginone enantiomers and superiority of (+)-halofuginone, are of great importance for future use of (+)-halofuginone as a DMD antifibrotic therapy.
Insights
(+)-Halofuginone, a specific form of an antifibrotic compound, improved muscle function and reduced fibrosis in Duchenne muscular dystrophy (DMD) mouse models. This enantiomer showed superior efficacy compared to the racemic mixture for potential DMD therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Muscle Physiology
Background:
- Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and fibrosis.
- Halofuginone, a febrifugine analog, has demonstrated antifibrotic properties in various models.
- Understanding the specific effects of halofuginone enantiomers is crucial for therapeutic development.
Purpose of the Study:
- To investigate the differential effects of (+)/(-)-halofuginone enantiomers on motor function and diaphragm pathology in mdx mice.
- To compare the efficacy of racemic halofuginone and its individual enantiomers in a mouse model of DMD.
Main Methods:
- Four-week-old male mdx mice were treated with racemic halofuginone, (+)-halofuginone, or (-)-halofuginone for 10 weeks.
- Motor coordination and balance were assessed.
- Diaphragm histopathology, collagen content, utrophin levels, and myofiber diameters were analyzed.
Main Results:
- (+)-Halofuginone significantly improved motor coordination and balance compared to controls and racemic halofuginone.
- Racemic and (+)-halofuginone reduced collagen content and degenerative areas in the diaphragm, with (+)-halofuginone being more effective.
- (+)-Halofuginone increased utrophin levels and myofiber diameters in the diaphragm, outperforming the racemic form.
Conclusions:
- The study demonstrates a differential therapeutic effect between halofuginone enantiomers in the mdx mouse model.
- (+)-Halofuginone exhibits superior antifibrotic and muscle-protective effects compared to the racemic mixture.
- These findings highlight the potential of (+)-halofuginone as a targeted antifibrotic therapy for Duchenne muscular dystrophy.
